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Summary The ability of the potent poly(ADP-rbose) polymerase (PARP) inhibitor. NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one) to
potentiate the cytotoxicity of a panel of mechanistically diverse anti-cancer agents was evaluated in L1210 cells. NU1025 enhanced the
cytotoxicity of the DNA-methylating agent MTIC, y-irradiation and bleomycin 3.5-, 1.4- and 2-fold respectively. The cytotoxicities of the
thymidylate synthase inhibitor, nolatrexed, and the cytotoxic nucleoside, gemcitabine, were not increased. Potentiation of MTIC cytotoxicity by
a delayed exposure to NU1025 was equally effective as by a simultaneous exposure to NU1025, indicating that the effects of NU1025 were
mediated by an inhibition of the cellular recovery. The recovery from potentially lethal ;--irradiation damage cytotoxicity in plateau-phase cells
was also inhibited by NU1025. Investigation of DNA strand breakage and repair in t-irradiated cells by alkaline elution demonstrated that
NU1025 caused a marked retardation of DNA repair. A structurally different PARP inhibitor, NU1064 (2-methylbenzimidazole-4-carboxamide).
also potentiated the cytotoxicity of MTIC. to a similar extent to NU1025. NU1064 potentiated a sublethal concentration of a DNA methylating
agent in a concentration-dependent manner. Collectively, these data suggest that the most suitable cytotoxic agents for use in combination
with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.
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Polv(ADP-ribose) polxmerase (PARP: EC 2.4.2.30) is an
abundant 1 16-kDa nuclear enzyme with approximately 2 million
molecules per (HeLa) cell: equi-alent to I molecule for every kb
of DNA. The enzyme comprises an N-tenminal DNA-binding
domain (DBD) containing two zinc fingers. w-hich recoglnize DNA
strand breaks. an automodification domain and a C-terminal
catalvtic domain. PARP can bind to undamaged DNA but has an
absolute requirement for catalxtic activation on DNA breaks.
Ahen activated. PARP catalyses the formation of long, homo-
poly mers of ADP-ribose on nuclear proteins usin, NAD- as a
substrate. The main protein acceptor is PARP itself (automodifica-
tion). but the enzN-me has also been shown to modify histones.
HMG proteins. topoisomerases. DNA polymerases and ligases
(see reviews by Cleaver and Morgan. 1991: Lautier et al. 1993: de
Murcia and Menissier de Murcia. 1994: Lindahl et al. 1995 and
references therein). The ADP-ribose polymers formed by PARP
are degraded by ADP-ribose glycohydrolase. and under conditions
of PARP stimulation by DNA damage a dy-namic sysstem of rapid
synthesis and deggradation exists causing rapid NAD- depletion
(see Boulikas. 1991 and references therein).
The activation of PARP by DNA strand breaks implies that it is
in-olved in the repair of such lesions. although the precise role of
the enzy-me remains to be elucidated. It has been proposed that the
ADP-ribose polI mer causes relaxation of chromatin at the site of
the DNA strand break. allowing access ofrepair enzymes (Althaus
et al. 1993 . Alternatively. poly(ADP-ribose) synthesized on PARP
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bound to nicked DNA miaht stabilize histone residues and main-
tain nucleosomal structure. thereby keeping the txwo DNA ends
correctly positioned for subsequent rejoining (Lindahl et al. 1995).
The possible involvement of PARP in DNA repair has stimu-
lated an interest in its role in determining the response to anti-
cancer therapies that damage DNA. The availabilitv of inhibitors
of PARP has greatly aided these studies (Shall. 1984). most of
which has-e investigated the potentiation of monofunctional alkyl-
atina agents and ionizing, radiation as these therapies are the most
potent actixators of PARP. althoug!h some other agents have also
been evaluated (reviewed in Griffin et al. 1995).
Studies of the potentiation of DNA-damaging agents by PARP
inhibition have primarilx used the benzamide inhibitors. However.
the benzamides are not very potent and. although their PARP
inhibitonr IC- concentrations are in the low micromolar range.
millimolar concentrations are invariably required to achieve
potentiation in cvtotoxicitv assays. Furthermore. the benzamides
also have other effects. most notably on de novo purine biosyn-
thesis (Cleaver. 1984: Hunting et al. 1985: Milam et al. 1986).
Nevertheless. trans-dominant inhibition of PARP. through over-
expression of the DBD. also sensitizes cells to y-irradiation and
alkylating acgents (Molinete et al. 1993: Kupper et al. 1995). an
observation that is consistent with the effects of the benzamides
being primarily caused by PARP inhibition. However. given the
high concentrations of benzamides required in cytotoxicity
studies. more potent and specific inhibitors of PARP are required
in order to assess the clinical potential of PARP inhibitors to
improve current cancer therapy.
Using rational drug desicgn. two novel series of PARP inhibitors
have been developed: the benzimidazole4-carboxamides and
'T'his paper is part 4 of the .senies Resistance Modift-ing Agents.: for par .see
Griffin et al 1996 h Pharn Si 2: 43-7.
1269prepared as previously described (Grnffin et al 1995. 1996). were
dissolved in DMSO at 100 imM and stored at -20°C. Gemcitabine
(a gift from Eli Lilly. Indianapolis. IN. USA) was dissolved in
water at 10 mnm and stored at -20°C. MTIC [5-(3-methyltriazen-l-
yl)imidazole-4-carboxamide: a gift from Dr C Bleasdale.
University of Newcastle upon Tyne. UK] and bleomycin
(Lundbeck. Milton Keynes. UK) were dissolved in DMSO and
used immediately. 3-Aminobenzamide (3AB; Pfaltz and Bauer.
Phase Separations. Deeside. UK) was dissolved in tissue culture
medium (see below) on the day of use by stirring for 4 h and filter
sterilized. Drugs were added to cell cultures so that the final
DMSO concentration was always 1% (v/v). All other chemicals
were obtained from Sigma (Poole. UK) unless stated otherwise.
Cells
B
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Figure 1 Chemical strctures of NU1025 (A) and NU1064 (B)
quinazolin4-[3H]-ones. which exhibit much greater potency than
the benzamides (Griffin et al. 1995. 1996). The potentiation of
DNA methylating agent-induced cytotoxicity and DNA strand
breakage by one of these novel PARP inhibitors (NU1025:
8-hydroxy-2-methylquinazolin4-[3H]one. Figure IA) has been
described previously (Boulton et al. 1995). The aims ofthe studies
reported here were to investigate the effects of NU1025 (IC,o for
PARP inhibition = 0.4 .LM) on the cytotoxicity of a range of anti-
cancer agents, and to compare the effects of quinazolinone
(NU1025) and benzimidazole (NU1064: 2-methylbenzimiidazole-
4-carboxamide: IC;,, for PARP inhibition = 1 Mk. Figure 1B)
PARP inhibitors on methylating agent-induced cytotoxicity. The
cytotoxic treatment studied were methylating agents (MTIC and
temozolomide). y-irradiation. bleomycin and anti-metabolites
(nolatrexed and gemcitabine). Studies with topoisomerase I and H
inhibitors are described elsewhere (Bowman et al. 1996 and manu-
script in preparation)
MATERIALS AND METHODS
Drugs
Nolatrexed (a gift from Agouron Pharmaceuticals. San Diego. CA.
USA) and temozolomide (a gift from the Cancer Research
Campaign. London. UK) were dissolved in dimethyl sulphoxide
(DMSO) at O nmi and stored at -200C. NU1025 and NU1064.
Murine leukaemia L 1210 cells were used to allow comparison
with the PARP inhibitory potency ofthe compounds that had been
determined previously using permeabilized L1210 cells (Griffin et
al 1995. 1996). Cells were maintained as exponentially growing
cultures (<8xlI0 cells ml-') in RPMI-1640 medium supplemented
with 10% (v/v) fetal calf serum (Sigma. Poole. UK). at 37°C in an
atmosphere of 5% carbon dioxide in air. The cell doubling time
was approximately 12 h. For experiments with the thymidylate
synthase inhibitor. nolatrexed. cells were adapted to grow in RPMI
medium supplemented with 10% (v/v) dialysed serum (to remove
thymidine) and maintained in this medium for at least 4 weeks
before cytotoxicity assays. when the cell doubling time was also
approximately 12 h. Cells were tested to exclude mycoplasma
contamination (Chen. 1977) every 4-8 weeks.
Cytotoxicity assays
L1210 cells were diluted to l0 ml-' in medium containing the
desired concentration of the cytotoxic drug. with or without the
PARP inhibitor, in duplicate wells of a six-well plate. After the
selected exposure period. cells were harvested by centrifugation
(200 g. room temperature) to remove the drugs. resuspended in
fresh medium and counted (Coulter Counter Z1: Coulter
Electronics. Luton. UK). Cell suspensions were then further
diluted and dispensed into sterile polyurethane tubes (Falcon.
Becton Dickinson. Oxford. UK) in triplicate at a suitable density
in 1 ml ofculture medium (estimated to give 10-60 colonies). and
5 ml of 0.15% (w/v) agarose (SeaKem ME Agarose. Flowgen.
Sittingbourne. UK) in culture medium was added. The tubes were
incubated for 1-2 weeks to allow colonies to appear and the
contents placed in dishes containing 1 ml 0.5 mg ml-' MTT (3-
[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide) to
stain the viable colonies. After 4 h colonies were counted and the
plating efficiency. relative to the appropriate control (DMSO alone
or PARP inhibitor alone). was calculated. DMSO control incuba-
tions gave approximately 100% plating efficiency.
In order to investigate ifthe potentiation of a cytotoxic agent by
NU1025 was dependent on the simultaneous presence of the
inhibitor. or if NU1025 would be equally effective when adminis-
tered after the cytotoxic agent had been removed. the following
protocol was employed: cells were exposed to varying concentra-
tions of MTIC for 20 min. duplicate samples were then harvested
by centrifugation and resuspended in drug-free medium or
medium containing 200 gm NU1025 for a further 16 h. In addi-
tion. cells were exposed to varying concentrations ofMTIC in the
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were exposed to a `Cs source (Gammacell 1000 Elite. Nordian
International. Canada) then incubated at 37C. in the presence or
absence of 200 im Ni 1025 for 2 h before determining colony
formation as described above. To insvestigate the repair of poten-
tially lethal damage. duplicate cultures ofcells were held at plateau
phase by maintaining, them at a density of 106 cells ml-' in condi-
tioned medium from plateau-phase cells (which ensured a
complete cessation of cell division without a decrease in cell
viability durinc the exposure period: data not shown) and exposed
to 8 Gy ofy-irradiation. Cells were kept on ice immediately before
and after irradiation. then incubated at 37C in the presence or
absence of 200 .iM NUT1025 for the time period indicated in the
results. counted and seeded for colony formation in 0.15%c (w/s)
agarose as above.
The degree of potentiation [enhancement factor (EF)] produced
bv the PARP inhibitor was calculated by comparing the IC9, or
ID90 [the concentration (C) ofdruc ordose (D) ofradiation causin,
90% cell death. i.e. a 10% relative plating efficiency] of the crto-
toxic agent alone with the ICg) or ID, in the presence of PARP
inhibitor.
EFI,, =IC., orID., controlfIC,, orID., + PARP inhibitor
Figure 2 Effect of NU1025 on the cytotoxicity of MTIC. Cells were exposed
to varying concentrations of MTIC for 20 min and resuspended in fresh
medium for 16 h (-) or medium containing 200 JM NU1025 for 16 h (=)
before seeding for colony formabon. In additon, cells were exposed to
varying concentrations of MT1C in the presence of 200 JM NU1025 for 20 min
and resuspended in fresh medium containing 200 gm NU1025 for 16 h (:)
before seeding for colony formation. Data are mean + s.d. of triplicate colony
counts from each of the cell populations exposed in duplicate. from a single
representative experiment with pooled data from three experiments given in
Table 1
presence of 200 gm NU1025 for 20 rmn. harvested and resus-
pended in fresh medium containing 200 im NU1025 for a further
16 h. After the 16-h incubation cells were counted and seeded for
colony formation as described above.
To study the effects of PARP inhibition on y-irradiated cells.
cultures were dispensed into sterile plastic bijoux bottles (Bibby
Sterilin. Aldershot. UK) and duplicate samples (cooled to 0-4C)
Alkaline elution
DNA strand break formation in druc-treated or irradiated cells was
measured by alkaline elution as previously described (Kohn et al.
1981 ). This technique employs filters that mechanically impede the
passage of DNA. such that the rate of elution through the filter is
inversely proportional to the length ofthe DNA strand. Treated cells
are co-eluted with intemal standard cells that hase been irradiated
immediately before elution in alkaline buffer. Measurement of the
proportion oftotal DNA from the treated cells remaining on the filter
compared with the percentage of the total DNA from the intemal
standards in each fraction collected gives the standardized elution
rate of the experimentally treated cells. Treated cells (40 ml.
2.5 x I0W ml-') were labelled wvith 14.8 kBq ml' [2-'4C]thNmidine
(1 96GBq mmol: Amersham International. Amersham. TK) for
24 h. Following a 4 h chase period in fresh medium. duplicate
Table 1 Potentiation of cytotoxic agents by PARP inhibitors
Cytotoxic treabTme Recovery IC,0 (units) EF b
MTIC 20 min 16 h drug-free medium 811 ± 328 (nM)
MTIC + 200 iM NU1025 16 h 200 iLM NU1025 220 ± 68 (nM)" 3.6 0.5
MTIC 16 h 200gM NU1025 234 ±35 (nm) 3.4-1.0
MTIC 16 h 791 ± 61 (nM)
MTIC + 200 gM NU1064 16 h 321 ± 171 (nM) 2.9 1.2
-y-Irradiation 2 h dnrg-free medium 6.36 ± 0.4 (Gy)
-,.-Irradiation 2 h 200 g NU1025 4.53 ± 0.5 (Gy)' 1.4 0.2
F-lrradiation 2 h 10 mM3AB 5.33 ± 0.61 (Gy)' 1.2 0.1
Bleomycin 16 h 47.9 ± 18.6 (IU x 10-3)
Bleomycin + 200 4M NU1025 16 h 24.3 ± 5.2 (IU x 10-3) 2 + 0.5
Figures are mean ± s.d. of three independent experiments. aIC., the concentration of drug or dose of radiation causing 90°o cell death (i.e. a 10%O relative
plating efficency) of the cytotoxic agent alone with the ICg or IDg in the presence of PARP inhibitor. Relative plating efficiency was calculated by comparison
with the plating efficiency of the appropriate control (DMSO or 200gM PARP inhibitor), relative plating efficienies for PARP inhibitor controls were 105 ± 14°o
and 54± 120/o for 200 JM NU1025 and NU1064 respectively. tEFw. enhancement factor. i.e. the ratio of the ICw of the cytotoxic agentaklne to the ICg in the
presence of PARP inhibitor. (EF. = IC.C controVllC , + PARP inhibitor.) Significant differences of cytotoxic agent + PARP inhibitor from cytotoxic agent alone are
given by 'P<z0.1 and 'P<c0.05.
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samples were transferred to sterile Bijoux bottles and irradiated as
described above. Cells were either eluted immediately or were incu-
bated at 37°C for 2 h in the presence or absence of200gM NU1025.
Atthe endofthe exposure period cells were harvested by centnfuga-
tion and resuspended in ice-cold PBS (Gibco. Paisley. UK) before
elution. Interal standard cells were labelled with 37 kBq ml-'
[methyl-3H]thymidine (1.85 TBq mmol1: Amersham) for 24 h.
chased for 4 h plus the exposure period of the experimental cells.
irradiated with 3 Gy andresuspended in ice-cold PBS before elution.
Duplicate aliquots of treated cells were allowed to settle on
to individual polycarbonate filters (pore size 0.8 gm. diameter
25 mm. Whatman International. Maidstone. UK), replicate
aliquots ofintemal standard cells were also added to all filters and
both treated and internal standard cells were allowed to settle on to
the filters by gravity in ice-cold PBS. A solution of 2% (w/v)
sodium dodecyl sulphate (SDS) in 25 mm EDTA pH 10 was added
to lyse the cells and the filters were then exposed to 0.5 mg ml'
proteinase K in lysis solution for 1 h. The filters were washed
three times with 20 mm EDTA pH 10 and eluted with 20mm
EDTA (acid form) + 1% (w/v) SDS adjusted to pH 12.1 with
tetrapropylammonium hydroxide (Aldrich. Gillingham. UK). The
elution rate was 2 ml h-' andeight 90-min fractions were collected
into scintillation vials containing 15 ml of scintillant (Optiphase
Hisafe 2, Fisons. Loughborough. UK). The filters were transferred
to scintillation vials. baked at 60°C in 0.4 ml of 1 M hydrochloric
acid for 1 h then neutralized with 2.5 ml of 0.4M sodium
hydroxide at room temperature for 15 min before adding 15 ml of
scintillant and counting with the eluted samples. The total radio-
activity collected in the fractions and hence that remaining on the
filters was determined. and the proportion of the total retained on
the filter for each of the 90 min intervals was calculated. The
proportion ofthe total '4C retained on the filter at each time point
was plotted against the proportion ofthe total 3H retained to stan-
dardize the assay against inter- and intra-assay variations in pump
efficiency.
Statistical analysis
Comparison ofdata sets was made by paired orunpaired Student's
two-tailed t-test analyses as appropriate using Graphad Instat soft-
ware (GraphPad Software. San Diego. CA. USA).
RESULTS
Monofunctional alkylating agents
Two monofunctional alkylating agents were used in these experi-
ments: MTIC. a very reactive DNA-methylating agent with a half-
life in aqueous medium of 8 min (Shealy and Krauth, 1966). and
the clinically used agent, temozolomide, which spontaneously
decomposes to yield MTIC with a half-life of 1.24 h in phosphate
buffer and 0.42 h in human serum (Stevens et al, 1987). NU1025
has previously been shown to potentiate the cytotoxicity of temo-
zolomide when cells were exposed to both drugs simultaneously
(Boulton et al. 1995). In order to investigate the mechanism of
NU1025 potentiation. experiments were performed with MTIC as
its rapid half-life allows a pulse exposure to the methylating
species. Exposure to MTIC and concomitant or sequential expo-
sure to NU1025 was used to determine if potentiation required
both drugs to be present at the same time. Cells were exposed for
20 min to MTIC followed by a 16-h recovery period in fresh
0
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Figure 3 Potentiation of MTIC cytotoxicity by NU1064. Cells were exposed
to varying c ations of MTIC in the presence (A) or absence (-) of
200 gm NU1064 for 16 h before seeding forcolonyformation. Data are
mean ± s.d. of triplicate coony counts from each of the ceU populabons
exposed in duplicate, from a single representative experiment with pooled
data from three experiments gven in Table 1
medium: 200gM NU1025 was either omitted from both incuba-
tions. added only to the recovery medium or present during both
the exposure and recovery periods. MTIC caused a concentration-
dependent decrease in cell survival and the cytotoxicity was
increased by NU1025 both when it was co-administered with the
MTIC or added after the MTIC had been removed (Figure 2).
Comparison of the IC, data (Table 1) demonstrates significant
potentiation (P < 0.05) in both cases. The potentiation was similar
(approximately 3.5-fold) for both simultaneous and delayed
NU1025 treatment (Table 1). confirming that the presence of
NU1025 during the repair phase alone was sufficient for potentia-
tion ofMTIC cytotoxicity. Similarexperiments with the bemzimi-
dazole. NU1064 (Figure 3) demonstrated that 200 gm NU1064
also caused a threefold enhancement of cytotoxicity (Table 1).
There was no significant reduction in cell survival following expo-
sure to 200 gm NU1025 alone but 200gM NU1064 reduced
survival by approximately 50%; this was accounted for in the
calculation ofrelative plating efficiency (see Methods).
The growth inhibition caused by NU1025 alone and the syner-
gistic effect of NU1025 on growth inhibition caused by a fixed
concentration of temozolomide has been described previously
(Boulton et al, 1995). In the current study the cytotoxicity of
increasing concentrations of the benzimidazole PARP inhibitor,
NU1064. alone and in combination with the same fixed concentra-
tion of temozolomide (100gM, a concentration causing 10%
reduction in cell survival), was investigated. The results were
normalized tocontrols withoutNUI1064, i.e. 1% DMSO or 100gIM
temozolomide alone. NU1064 alone was slightly cytotoxic.
resulting in a 45% reduction in cell survival at 200gs, the highest
achievable concentration (Figure 4). There was a very marked
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Figure 4 PotentiatKon of the cytotoxicity of 100 uM temozolomide by
NU1064. Cells were exposed to increasing concentrations of NU1064 in the
presence (7) or absence (V) of 100 gM temozokomide for 16 h before
seeding for colony formation. (Data norrnalized to DMSO or temozolomide
alone controls: exposure to 100 gm temozolomide alone results in
approximatety 900% cell survival.) Data are means + s.d. of triplicate colony
counts from each of the cell populations exposed in duplicate, from a single
representative
effect of increasing NU1064 concentrations on the cytotoxicitv of
100 JIM temozolomide. resulting in a 98% reduction in cell
survival at 200 -iM NU1064 (Figure 4). the IC-o for NLT1064 +
100 JIM temozolomide being 46 gtm.
f-Irradiation
Exponentially grow-ing cells exposed to y-irradiation. followed by
a 2-h recovery period. display a dose-related reduction in survival
(Figrure 5A). If the recovery was in the presence of 200 j.si
NU1025 the survival (ICG) was significantly (P<0.05) reduced
by a factor of 1.4 (Figure 5A. Table 1). For companrson, the effect
of 10 m-M 3-aminobenzamide (3AB) was also investigated. a
concentration chosen to be equipotent with that ofNU1025 on the
basis of the inhibition of L1210 PARP activitv in a permeabilized
cell assay (Griffin et al. 1995). The potentiation ofy-irradiation by
3AB was less than with NU1025 (EF9 = 1.2). and only marginally
significant (P < 0.1). Furthermore. 10 mm 3AB alone caused an
18 ± 13% reduction in cell survival (compared with 3 ± 5% reduc-
tion for NU1025). possibly a reflection of the effect of 3AB on
enzymes other than PARP.
To investigate the effect of NUJ1025 and 3AB on the repair of
potentially lethal damage. cells were held at plateau phase and
exposed to 8 Gy ofy-irradiation. Cells were then seeded for colony
formation. either without recovery or allowed to recover in the
presence or absence ofthe PARP inhibitor for 2 or 4 h after irradia-
tion. As shown in Figure SB. there was a slight recovery ofthe cells
with time in the absence of PARP inhibitor: however. in the pres-
ence of 200 ptM NV 1025 or 10 Xm1 3AB recovery was inhibited.
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Figure 5 Effect of NU1025 and 3AB on the cytotoxicity of --irradiation.
A Exponentially growing cells were exposed to varying doses of -tLirradiation
followed by a 2-h recovery period in control medium (0), 200 gM NU1025
or 10 mm 3AB (7) before seeding for colony formation. B Recovery from
potentially lethal k-irradiation damage in the presence or absence of NU1025
or 3AB. Plateau-phase cells were exposed to 8 Gy of y-irradiation and
allowed to recover for up to 4 h in control medium (0) or medium containing
200 gm NU1025 (.), or 10 mm 3AB (7) before seeding for colony formation.
Data are mean ± s.d. of triplicate colony counts from each of the cell
populations exposed in duplicate, from a single representative experiment
with pooled data from three expenments of the type shown in A given in
Table 1
The effects ofNU1025 on the repair ofDNA damaged by y-irradi-
ation was measured by alkaline elution. The elution profiles of cells
exposed to y-rays and eluted immediatelv. or after recovery for 2 h in
the presence or absence of NU1025. are shown in Figure 6. The
elution profiles of cells allowed to recover for 2 h after inradiation
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Figure 6 Effect of NU1025 on the repair of DNA damage after potentialty
lethal y-irradiation damage. Cells were exposed to 8 Gy of y-irradiaton and
eluted immediatety (V) or allowed to recover for up to 2 h in control medium
(A) or medium containing 200 gM NU1025 ( ) compared with unirradiated
control cells eluted with (-) or wrthout (U) the 2-h recovery incubation and
unirradiated cells exposed to NU1025 for 2 h (_) before determination of
DNA strand breakage by alkaline elution. Data are from representative elubon
profiles of duplicate samples from a single representative experiment
were indistinguishable from profiles of control cells. demonstratin,
that complete repair had occurred in the recovery period- The elution
profiles ofcells exposed to NU1025 dungn the recovery period were
intermediate between the profiles ofthe control cells and cells irradi-
ated and eluted without recovery. indicating that repair A-as hindered
by NU1025 but not completely blocked a result consistent with the
cvtotoxicitx data.
Bleomycin
A concentration-dependent increase in cytotoxicity Aas observed
following a 16-h exposure to the radiomimetic drug, bleomvcin.
and cytotoxicio-swas enhanced twofold by co-exposure to NU1025
(Figure 7. Table 1): however. the potentiation was only marginallv
significant (P < 0.1 ).
Nolatrexed
L1210 cells were adapted to growth in dialysed serum as the
thvmidine concentration of undialysed serum was sufficient to
prevent the cytotoxicity of nolatrexed during a 16-h exposure
period (data not shown). Nolatrexed wvas selected for these studies
as. unlike classical antifolate thymidylate synthase inhibitors. it
does not require active uptak-e or polyglutamation (Webber et al.
1996). In dialysed serum there was a decrease in cell survival
followinc a 16-h exposure to increasing concentrations of nola-
trexed. However. there was no enhancement of nolatrexed cyto-
toxicity by co-exposure to NU1025 (Figure 8A}: the ICSo for
nolatrexed alone was 1.57 ± 0.66 Jm. and in the presence of
200JM NU1025 was 2.42±1.42 -i (P>0.1). NU1025 also
failed to potentiate the classical antifolate thymidylate synthase
inhibitor. CB3717 (data not shown).
[Bleomycin](IU ml')
Fgure 7 Effect of NU1025 on the cytotoxicity of bleomycin. Cells were
exposed to varying concentrations of bleomycin in the presence (X) or
absence (e) of 200 gm NUl 025 for 16 h before seeding for colony formation.
Data are means ± s.d. of triplicate colony counts from each ofte cell
populations exposed in duplicate, from a single representative experiment
Gemcitabine
The novel anti-cancer nucleoside analogue gremcitabine WdFdCH is
phosphorylated intracellularlv to dFdCDP. vAhich inhibits nrbo-
nucleotide reductase. and dFdCTPC which is incorporated into DNA
(Plunkett et al. 1995). L1210 cells were exposed togremcitabine for
16 h. resulting, in concentration-related cvtotoxicity that wvas not
potentiated by NUJ1025 (Figure 8B): the IC, forgaemcitabine alone
was 7.9 n-Nw and in the presence of200 JIm NU1025 was 8.4 nmt.
DISCUSSION
Investigations ofthe effects ofPARP inhibition on the cvtotoxicitV
of DNA-damaging anti-cancer agents have been assisted by the
recent development of inhibitors that are markedly more potent
(> tenfold). and possibly more specific. than the classical benza-
mide inhibitors. The primary aim of this study as to evaluate the
effects of two representative examples of the recently developed
PARP inhibitors on the cv-totoxicitv of a range of different anti-
cancer aaents in order to select suitable agents for preclinical in
vivo and. ultimately. clinical studies. In addition. studies were
performed to investigate whether these PARP inhibitors func-
tioned by inhibition of repair/recovery. or by a mechanism that
requires the cytotoxic agyent and the PARP inhibitor to be present
at the same time.
The majonrtx of studies on the potentiation of cvtotoxicity by
PARP inhibition have used alky lating (particularly monofunc-
tional alkylating) agents and in the studies described here the
greatest potentiation was observed with MTIC (Table 1). MTIC is
not clinically useful as it is too reactive. but temozolomide. which
breaks down chemically to produce MTIC. is currently undergoing
clinical trials (Newlands et al. 1997). Previous studies. also in
L1210 cells (Boulton et al. 1995). have demonstrated that NIT1025
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Figure 8 Effect of NU1025 on the cytotoxicity of the anti-metabolites
nolatrexed and gemcitabine. A Cells were exposed to varying concentrations
of nolatrexed in the presence ( ) orabsence (-) of 200 gm NU1025 for 16 h
before seeding for colony formation. Data are means + s.d. of tripicate colony
counts from each of the cell populations exposed in duplicate. from a single
representative experiment. B Cells were exposed to varying concentratons of
gemcitabine in the presence ( ) or absence (0) of 200 gm NU1025 for 16 h
before seeding for colony formation. Data are mean ± s.d. of triplicate colony
counts from each of the cell populations exposed in duplicate. from a single
experiment
increases growth inhibition induced by a low fixed (100 JIM)
concentration of temozolomide in a concentration-dependent
manner. The enhancement of the cytotoxicitx (clonogenic assay)
of 100 Im temozolomide by NU1064 (Figure 4) also illustrated
PARP inhibitor concentration dependence. The results suggest that
the enhancement of temozolomide cvtotoxicitv is related to the
degree of PARP inhibition. and that the concentration of the tw-o
PARP inhibitors required to reduce cell growth and survival. in the
presence of 100 gm temozolomide. by 50%c in the two studies were
remarkablx similar (41 and 46nm for NU1025 and NU1064
respectivelx).
Although NU1064 is 2.5-fold less potent than NU1025 in
permeabilized L1210 cell PARP inhibition assavs (Gnrffin et al.
1995. 1996). NU1064 caused a similar potentiation of MTIC cyto-
toxicitv (threefold) compared with NU,1025 (3.5-fold potentia-
tion). The concentration of NUT1025 mav has-e been in excess of
that needed for maximumcytotoxic potentiation as 50 msi N- 1025
has been demonstrated to be sufficient to give maximum potentia-
tion of temozolomide growth inhibition (Boulton et al. 1995).
NU1025 also increased the cytotoxicity of y-irradiation to expo-
nentially arowing L1210 cells. affecting both the shoulder and the
slope of the survival curve (Figure 5A). Similar results have been
observed in exponentially growing V79 cells with 500 Jim
PD128763 (Arundel-Suto et al. 1991). In the studies reported here.
a 2-h recovery period ± NU1025 was used. as preliminary experi-
ments had shown that no greater potentiation Awas achieved bv
extending the period to 8 h (data not shown). This obserxation is in
agreement with previously reported results showing that 2 h is
long, enough to vield near maximum radiosensitization with other
PARP inhibitors (Ben-Hur et al. 1985: Arundel-Suto et al. 1991).
Alkaline elution studies (Figure 6) confirm that DNA repair is
Xvirtuallx complete 2 h after irradiation. Howuever. in studies on the
repair of potentially lethal irradiation damage. the sunriving frac-
tion increased not only during the first 2 h of the recovery period
but also continued to increase for a further 2 h (Fiaure Sb). In these
studies cells were held in plateau phase (i.e. growth arrested) to
allow DNA repair before being 'fixed' by DNA replication.
The cvtotoxicity of bleom cin was increased twofold by
NU1025. which confirms data obtained w-ith the benzamide PARP
inhibitors: For example. 1 mrm 3AB has been shown to cause a 2.4-
fold reduction in the IC; of bleomycin in growth inhibition assays
in L1210 cells (Kato et al. 1988). and 3-methoxNbenzamide
(2.5 mxt) and 3AB (5 mm) both caused a threefold potentiation of
the cytotoxicity of bleomycmn (10 pzg ml') in Chinese hamster
oxarv (CHO) cells (Huet and Laval. 1985).
There was no potentiation of the cvtotoxicity of the thymidylate
svynthase (TS) inhibitor nolatrexed. Ifanvthing. there w-as a modest
protection. although this was not significant by statistical analysis.
A lack of potentiation would not be predicted from the suggested
role of PARP in base excision repair. and the proposed mechanism
of cvtotoxicity of TS inhibitors. TS inhibitor cvtotoxicitx is
thought to involve base excision repair as a result of dUTP pool
elexations. which lead to extensive uracil misincorporation into
DNA. Excision of misincorporated uracil by the base excision
repair enzyme. uracil glvcosvlase. leads ultimately to DNA strand
breakaae and cell death. the elevation of dUTP pools correlatinc
well with DNA strand breakaae in TS-inhibited cells (Curtin et al.
1991). However. consistent with the current results are those of
Prise et al (1986). who showed that in HeLa cells the survixing
fraction following a 24-h exposure to methotrexate alone was
0.31 ± 0.02. whereas co-incubation with 5 mM\ 3AB increased this
to 0.41 ± 0.10. Similarlv. in a studx in CHO cells. 3 mM\ 3AB had a
protective effect on the cytotoxicitv offluorodeoxvuridine (FUTdR:
another TS inhibitor) even though DNA strand break levels were
increased (Willmore and Durkacz. 1993). These latter authors
proposed that the NAD+ depletion induced by FLTdR may
contribute to the cvtotoxicitv of TS inhibitors, and hence the
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prevention of this depletion by 3AB may exert a protective effect.
In the studies described here. a modest protection from gem-
citabine-induced cytotoxicity by NU1025 wvas also observed. S-
phase cells that most actively incorporate the drug are the most
sensitive to gemcitabine (Huang and Plunkett. 1995). and protec-
tion against a v-ariety of S-phase acting drugs (hydroxyurea.
fluorodeoxvuridine and thioguanine) by 3AB has been reported
and attributed to the cytostatic effects ofthe benzamides (Moses et
al. 1988). The growth-inhibitory effects of NU1025 alone in
L1210 cells has been described previously: IC for a 48 h expo
sure is 410 Im (Boulton et al. 1995). It is possible that the mildly
cvtostatic effect of NUL1025 at 200 -iM may hinder entry into S-
phase and hence protect cells from agents acting in this phase.
such as the anti-metabolites gemcitabine and nolatrexed.
PARP inhibitors are considered to potentiate cytotoxic arents bv
inhibiting DNA repair and hence the recovery from genotoxic
insult. In order to verify that NU1025 was acting by repair inhibi-
tion. the survival of cells exposed to an alkylating agent or
ionizing radiation. with a recovery period in the presence or
absence of NU1025. were compared. The highly reactive methyl-
ating, agent MTIC was selected in order to achieve rapid induction
of DNA damage for a limited period. NUT1025 caused a similar
potentiation ofMTIC cytotoxicity w-hether it was present from the
beginningr of the experiment or added only after the MTIC had
been removed. This result indicates that NU1025 does not interact
with MTIC to influence the initial level of DNA damage. but
rather that it suppresses recovery. In the case of y-iradiation. both
200g.m NJ1025 and 10 mM 3AB inhibited recovery from poten-
tially lethal damage. DNA repair following y-irradiation by
NU1025 was investigated by alkaline elution. and 2 h in drur-free
medium at 37°C was sufficient to pernit complete repair of DNA
strand breaks. NU1025 significantly retarded the repair of DNA
strand breaks but did not block it completely. Taken together these
data indicate that NU1025 is indeed inhibiting the repair of alkyl-
ating agent- and y-irradiation-induced DNA damage. and that this
effect underlies the potentiation produced by PARP inhibition.
The normal growth and development of PARP knockout mice
(Wang et al. 1997). which exhibit normal DNA repair capacity
after MNNG exposure. suggests that PARP activity is not neces-
sary for cell survival. However. the use of PARP inhibitors to
retard DNA repair and hence increase the cytotoxicitv of certain
classes of anti-cancer agrents remains a viable option as the effects
ofinhibited PARP are arguably different from those ofPARP defi-
ciency. This difference has been most clearly illustrated bv the
work of Satoh and Lindahl (1992). who demonstrated that cell
extracts depleted of PARP (analooous to PARP -I- mice) could
repair nicked DNA with similar efficiency to those containing
PARP. As expected. in whole-cell extracts containing PARP. the
absence of NAD+ or the presence of 3-aminobenzamide inhibited
DNA repair. Thus. the inhibition of PARP has a deleterious effect
on DNA repair. whereas its removal is neutral. A similar situation
to inhibited PARP is found when the DNA binding domain (DBD)
is transfected into cells. resulting in the dominant negative inhibi-
tion of PARP activity (Mohnete et al. 1993). In this system the
DBD binds to the DNA nick and. as there is no catal-tic or auto-
modification domain. no automodification and dissociation of the
DBD occurs. Lack of dissociation prevents access of full-length
PARP and DNA repair (Molinete et al. 1993). On the basis of this
model it may be no coincidence that during apoptosis PARP is
cleaved into twofragments. onecomprising the DBD and the other
the automodification and catalytic domains (Kaufmann et al.
1993). Cleavage would presumably be analogous in effect to the
overproduction ofthe DBD and the use of PARP inhibitors. i.e. an
inhibition ofDNA repair. which is presumably counter-productiVe
during programmed cell death.
In recent years considerable effort has been devoted to the
investigation of the role of PARP and its inhibition in the cvto-
toxicitv of anti-cancer acents using a wide variety of molecular
biological approaches. as w-ell as inhibitor studies. The precise role
of the enzyme still remains to be fully elucidated. but the use of
the new generation of potent and structurally different PARP
inhibitors mav facilitate the probing of its function. The data
presented here. using two novel potent inhibitors that are struc-
turallv different from the classical benzamides. supports many of
the studies w-ith the benzamides and conclusions drawn from them.
Furthermore. these data suggest that for the preclinical evaluation
of PARP inhibitors it would be appropriate to use combinations
with alkvlating agents. bleomvcin and ionizinc radiation. but not
antimetabolites.
ABBREVIATIONS
NlT1025. 8-hvdroxv-2-methylquinazolin4-[3H]one: N'U1064. 2-
methvlbenzimidazole-4-carboxamide: 3AB. 3-aminobenzamide:
DBD. DNA bindingy domain: IC. the concentration of druc
causing 90% cell death: ID,. dose of radiation causing 90% cell
death: EF90 enhancement factor(ICg,- orID90controUIC, or ID, +
PARP inhibitor): MNNG. N-methvl-M-nitro-N-nitrosoguanidine:
MTIC. 5-(3-methyltriazen- 1-vl)imidazole-4-carboxamide: MTT.
3-[4.5-dimethylthiazol-2-vl]-2.5-diphenvltetrazolium bromide:
PBS. phosphate-buffered saline: SDS. sodium dodecyl sulphate:
TS. thvmidylate synthase.
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